TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05826327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: The drug esketamine will be added to the experimental group as opposed to the control group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil for labour analgesia in the control group
Study: NCT06366386

Intervention type: BEHAVIORAL
Intervention: Screening and treatment of hypertension among PLHIV in DSD models for HIV
Description: In all DSD models of HIV, participants will receive screening for HTN (BP measurement), treatment of hypertension using a simplified protocol of amlodipine, hydrochlorothiazide and Losartan in a stepwise manner and laboratory monitoring for HTN medication adverse events.
Study: NCT06592144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (200mg/3ml)
Description: It will be administered intramuscularly every 5 days, totaling 3 doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sesame oil (3ml)
Description: It will be administered intramuscularly every 5 days, totaling 3 doses.
Study: NCT06602674

Intervention type: OTHER
Intervention: Observe the medical images
Description: Observe the medical images via work station or local image analysing software

Intervention type: OTHER
Intervention: Observe the medical images
Description: Observe the medical images via work station or local image analysing software

Intervention type: OTHER
Intervention: Observe the medical images
Description: Observe the medical images via work station or local image analysing software

Intervention type: OTHER
Intervention: Observe the medical images
Description: Observe the medical images via work station or local image analysing software

Intervention type: OTHER
Intervention: Feature extraction
Description: Extracting image feature via radiomics or deep learning methods

Intervention type: OTHER
Intervention: Feature extraction
Description: Extracting image feature via radiomics or deep learning methods

Intervention type: OTHER
Intervention: Feature extraction
Description: Extracting image feature via radiomics or deep learning methods

Intervention type: OTHER
Intervention: Feature extraction
Description: Extracting image feature via radiomics or deep learning methods
Study: NCT05251727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thrombomodulin alfa
Description: Weight based dose of reconstituted treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weight based dose of reconstituted treatment
Study: NCT06590532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair or aorto iliac endovascular revascularisation with Fusion imaging system Cydar-EV
Description: Cydar-EV image fusion is a CE-marked medical device, which instead of a table-tacked overlay uses computer vision to fuse pre-procedural 3D images with intra-operative 2D fluoroscopy automatically and in real-time.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular aneurysm repair or aorto iliac endovascular revascularisation without Fusion imaging system Cydar-EV
Description: patients will be assigned either to an endovascular repair using standard X-ray fluoroscopy imaging alone (the current reference standard)
Study: NCT06667674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for prolonged grief
Description: Participants will undergo a 10-week internet-delivered, therapist-led cognitive behavioral therapy treatment (iCBT) for prolonged grief, which includes psychoeducation about grief and common grief reactions, exposure, cognitive restructuring and behavioral activation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will undergo a 10-week internet-delivered, therapist-led treatment, which includes psychoeducation about grief and common grief reactions.
Study: NCT06670053

Intervention type: DRUG
Intervention: Testosterone
Description: Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician.

Intervention type: DRUG
Intervention: Testosterone
Description: Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician.
Study: NCT06540716

Intervention type: DEVICE
Group type: OTHER
Intervention: Inspire System
Description: Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.
Study: NCT06615752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea and quercetin + docetaxel
Description: green tea and quercetin supplements in combination with docetaxel infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + docetaxel
Description: Placebo will be given along with docetaxel chemotherapy
Study: NCT06619184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NCEHFORSCS transplantation
Description: One vitiligo lesion of participans treated with NCEHFORSCS transplantation including follicle unit extraction (FUE) procedure from the occipital area, laboratory procedure for preparation of cell suspension, and transplantation of NCEHFORSCS.
Study: NCT05763316

Intervention type: OTHER
Intervention: SNAP-II
Description: Calculate Score for Neonatal Acute Physiology II

Intervention type: OTHER
Intervention: SNAPPE-II
Description: Calculate Score for Neonatal Acute Physiology Perinatal Extension II

Intervention type: OTHER
Intervention: STOPS
Description: Calculate Sensorium, temperature, oxygenation, perfusion, skin color, and blood sugar score

Intervention type: OTHER
Intervention: MSNS
Description: Calculate Modified Sick neonatal Score

Intervention type: OTHER
Intervention: nSOFA
Description: Calculate neonatal sequential organ failure assessment
Study: NCT05039385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program focused on resistance training
Description: The program will be carried out by a personal trainer. To ensure correct execution, given that the groups will be of a maximum of 5 people. Each session will include:~A) Warm up: movility exercises and coordination games B) Main part: 3 exercises will be included to strengthen different muscle groups (pull , bench press and back squat). Velocity based training (VBT) will be used to control load. 3 sets of 16-30 repetitions mantaining the speed between Light (estimated loss of speed of the series 5-10%).~C) Cool down: feedback with patients based on the work of Stiles-Shields (2015).~Specific training content will focus on safety, while re-educating patients on proper exercise methods, motivation-related attitudes, and transparency on health benefits and potential harms as a result of increased exercise.
Study: NCT05845593

Intervention type: OTHER
Intervention: Decision Support Test
Description: LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE
Study: NCT06093503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion
Study: NCT04822571

Intervention type: OTHER
Group type: OTHER
Intervention: Reliability of 3D motion analysis protocol
Description: The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.

Intervention type: OTHER
Group type: OTHER
Intervention: Reliability of 3D motion analysis protocol
Description: The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
Study: NCT05581264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education Program
Description: diabetes self-management education and counseling program with follow-up via phone for the intervention group for 24 weeks
Study: NCT05926193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailor Food Bags
Description: The treatment group will participate in 6 nutrition workshops over the course of 6 months as well as receive weekly food bags that have been tailored for a DASH diet.
Study: NCT05254210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Device (Potenza™)
Description: Test spots may be performed prior to the first treatment. Following test spots, for the treatment, the tip will be placed in contact with the skin. Parameters may be adjusted throughout the treatment and will determined by the Clinician.
Study: NCT05645185

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis test
Description: Tests can be used: immunofluorescence, immunodot, western blot, tests CBA on sera or CSF.
Study: NCT06619184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPG procedure
Description: Another vitiligo lesion treated with MPG procedure~Follow up The dressing was removed by the researcher on day 8 The participants were asked to attend for follow-up at the clinic on week 2, 4, 8, 12, and 16 after the two procedure were done.~At 2, 4, 8, 12 and 16 weeks of follow-up visits, any possible complications were evaluated and digital photographs of the lesions were taken for evaluating the two procedure efficacy using its parameter: appearance of repigmentation (AOR), total number of repigmentation NSV lesions, extent area of repigmentation, and color match
Study: NCT06623591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active Transcutaneous auricular vagus nerve stimulation
Description: Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Transcutaneous auricular vagus nerve stimulation
Description: In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
Study: NCT05934565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Steps
Description: Integrated website, activity tracker, and mind-body training
Study: NCT05628545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GDKM-100 injection
Description: Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
Study: NCT04762966

Intervention type: DRUG
Intervention: Metformin
Description: Level of Metformin blood concentration

Intervention type: DRUG
Intervention: Metformin
Description: Level of Metformin blood concentration
Study: NCT06133439

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Colorectal Screen rates with implementation of evidence-based intervention
Description: Mailed FIT kits, Cologuard, and diagnostic colonoscopies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Colorectal Screen rates with implementation of evidence-based intervention
Description: Mailed FIT kits, Cologuard, and diagnostic colonoscopies.
Study: NCT06473428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory muscle training
Description: Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: respiratory muscle training
Description: Inspiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Training
Description: Expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Controlled Expiratory Muscle Training
Description: Placebo-controlled expiratory muscle training with two sessions per day, five repetitions per session, six days a week for eight weeks.
Study: NCT06139458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Participants will receive cryotherapy on both hands and feet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Participants will receive cryotherapy on both hands and feet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compression
Description: Participants will receive compression on both hands and feet
Study: NCT05822856

Intervention type: OTHER
Intervention: Blood sampling and others interventions
Description: Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests

Intervention type: OTHER
Intervention: Blood sampling and others interventions
Description: Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests

Intervention type: OTHER
Intervention: Blood sampling and others interventions
Description: Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests

Intervention type: OTHER
Intervention: Blood sampling and others interventions
Description: Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests

Intervention type: OTHER
Intervention: Blood sampling and others interventions
Description: Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
Study: NCT05619848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: 0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: 0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: 0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
Study: NCT05204979

Intervention type: OTHER
Intervention: Vaginal Versus Sublingual misoprostol
Description: Insertion failures of intra uterine devices and cervical problems seem to occur more often among women who have never delivered vaginally. Several studies have shown the benefit of misoprostol as a cervical ripening agent in nonpregnant women. This trial will compare the effect of vaginal versus sublingual misoprostol prior to insertion of an intrauterine device in multiparous women delivered by CS.
Study: NCT04725747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam/Ketamine HCl 3mg-50mg sublingual
Description: Single sublingual administration of Midazolam/Ketamine HCl 3mg-50mg sublingually prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 3mg Sublingual
Description: Single sublingual administration of Midazolam 3mg sublingually prior to surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50mg Sublingual
Description: Single sublingual administration of Ketamine HCl 50mg sublingually prior to surgery
Study: NCT05859984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human interferon ω spray
Description: 8 ml/bottle（contain 2 million IU recombinant human interferon ω）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human interferon ω spray
Description: 8 ml/bottle（contain 2 million IU recombinant human interferon ω）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human interferon ω spray
Description: 8 ml/bottle（contain 2 million IU recombinant human interferon ω）
Study: NCT06289738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICF
Description: Matching the answers given to the question set consisting of 6 open-ended questions with ICF
Study: NCT05722184

Intervention type: DIAGNOSTIC_TEST
Intervention: BactInsight blood culture system
Description: A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.

Intervention type: DIAGNOSTIC_TEST
Intervention: BactInsight blood culture system
Description: A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.

Intervention type: DIAGNOSTIC_TEST
Intervention: BactInsight blood culture system
Description: A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
Study: NCT06485908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of axitinib in combination with etoposide
Description: 1. st stage:~   * Axitinib (Inlyta®) PO, in the morning and in the evening every day~  * Level -1 : Dose 1.2 mg/m²~  * Level 1: Dose 1.6 mg/m²~  * Level 2: Dose 2.0 mg/m²~  * Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1~2. nd stage:~   * Axitinib (Inlyta®) dosing as selected at the 1st stage~  * Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)
Study: NCT05337124

Intervention type: DRUG
Intervention: LUPKYNIS
Description: LUPKYNIS treatment per the approved US Prescribing Information
Study: NCT04769401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Progesterone group
Description: Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Progesterone group
Description: Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.
Study: NCT05950126

Intervention type: OTHER
Intervention: pain catastrophizing scala
Description: The PCS, a 13-item self-report inventory used to determine the extent to which individuals catastrophize in response to pain, was developed. Total possible scores range from 0 to 52, with higher scores indicating negative results.~The Turkish version was tested for reliability and validity and the Cronbach alpha coefficient was measured at 0.90. PCS scores of 16 or lower are regarded as normal, and scores of 17 or above as high.

Intervention type: OTHER
Intervention: pain catastrophizing scala
Description: The PCS, a 13-item self-report inventory used to determine the extent to which individuals catastrophize in response to pain, was developed. Total possible scores range from 0 to 52, with higher scores indicating negative results.~The Turkish version was tested for reliability and validity and the Cronbach alpha coefficient was measured at 0.90. PCS scores of 16 or lower are regarded as normal, and scores of 17 or above as high.
Study: NCT06479057

Intervention type: OTHER
Intervention: Supportive Care Pathway
Description: All pathways include a medical consultation with comprehensive needs assesment and evidence-based coordinated supportive care referrals at institutional and community-based level.
Study: NCT05758038

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation/Microwave ablation
Description: thermal ablation by radiofrequency and Microwave

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation/Microwave ablation
Description: thermal ablation by radiofrequency and Microwave
Study: NCT06626984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound sodium lactate solution
Description: Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound sodium lactate solution
Description: Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
Study: NCT06626581

Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine excess
Description: Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) ≥300μg/L

Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine suitable
Description: Iodine suitable areas: water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.